A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

ClinicalTrials.gov ID: NCT04557462

Public ClinicalTrials.gov record NCT04557462. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 7, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan in Adult Participants With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301

Study identification

NCT ID: NCT04557462
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 540 participants

Conditions and interventions

Conditions

Primary IgA Nephropathy

Interventions

LNP023 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 19, 2021
Primary completion: Dec 3, 2030
Completion: Dec 3, 2030
Last update posted: May 5, 2026

2021 – 2030

United States locations

U.S. sites: 16
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
AZ Kidney Dise and Hypertension Ctr	Glendale	Arizona	85306	Recruiting
Kaiser Permanente	San Diego	California	92111	Active, not recruiting
North America Research Institute	San Dimas	California	91773	Active, not recruiting
University of Colorado Anschutz	Aurora	Colorado	80045	Active, not recruiting
Nephrology Associates PA	Newark	Delaware	19713	Withdrawn
CaRe Research	Chubbuck	Idaho	83202	Active, not recruiting
Nep Assoc of Northern Illinois	Hinsdale	Illinois	60521	Active, not recruiting
Johns Hopkins Hospital	Baltimore	Maryland	21287	Active, not recruiting
Brigham and Womens Hosp Harvard Med School	Boston	Massachusetts	02115	Completed
Mayo Clinic Rochester	Rochester	Minnesota	55905	Recruiting
Clin Rsrch Consult a JCCT Company	Kansas City	Missouri	64111	Active, not recruiting
DaVita Clinical Research	Las Vegas	Nevada	89146	Active, not recruiting
New Jersey Kidney Care	Jersey City	New Jersey	07305	Active, not recruiting
Col Uni Med Center New York Presby	New York	New York	10032	Recruiting
Dallas Renal Group	Dallas	Texas	75230	Active, not recruiting
Prolato Clinical Research Center	Houston	Texas	77054	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 145 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04557462, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 5, 2026 · Synced May 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04557462 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →